Biogen (BIIB) Capital Expenditures (2009 - 2026)
Biogen (BIIB) posted quarterly Capital Expenditures of $40.9 million for Q2 2026, up 53.76% year-over-year from $26.6 million in Q2 2025, and down 20.12% quarter-over-quarter from $51.2 million in Q1 2026.
Biogen (BIIB) Capital Expenditures (2009 - 2026) Analysis & Trends
Biogen's Capital Expenditures history runs 18 years deep, the most recent figure standing at $40.9 million for Q2 2026.
- In Q2 2026, Capital Expenditures rose 53.76% year-over-year to $40.9 million; the TTM figure through Jun 2026 stood at $182.2 million (up 32.03% YoY), while the FY2025 annual figure was $153.8 million, changed 0.07% from the prior year.
- Capital Expenditures for Q2 2026 stood at $40.9 million, down from $51.2 million in the prior quarter.
- The five-year high for Capital Expenditures was $86.4 million in Q4 2022, with the low at $26.6 million in Q2 2025.
- The 5-year median for Capital Expenditures is $46.0 million (2024), against an average of $50.9 million.
- The sharpest annual moves came in 2023 and 2024: Capital Expenditures jumped 92.41% in 2023, then sank 52.83% in 2024.
- Biogen's Capital Expenditures stood at $86.4 million in 2022, then dropped by 24.54% to $65.2 million in 2023, then plunged by 39.72% to $39.3 million in 2024, then grew by 11.7% to $43.9 million in 2025, then decreased by 6.83% to $40.9 million in 2026.
- Business Quant data shows BIIB's Capital Expenditures at $40.9 million in Q2 2026, $51.2 million in Q1 2026, and $43.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.32 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 322.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 893.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 321.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 513.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 140.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 533.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -440.07 Mn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 40.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.90 Mn |
| Jun 30, 2026 | 40.90 Mn |
| Mar 31, 2026 | 51.20 Mn |
| Mar 31, 2026 | 51.20 Mn |
| Dec 31, 2025 | 43.90 Mn |
| Dec 31, 2025 | 43.90 Mn |
| Sep 30, 2025 | 46.20 Mn |
| Sep 30, 2025 | 46.20 Mn |
| Jun 30, 2025 | 26.60 Mn |
| Jun 30, 2025 | 26.60 Mn |
| Mar 31, 2025 | 37.10 Mn |
| Mar 31, 2025 | 37.10 Mn |
| Dec 31, 2024 | 39.30 Mn |
| Dec 31, 2024 | 39.30 Mn |
| Sep 30, 2024 | 35.00 Mn |
| Sep 30, 2024 | 35.00 Mn |
| Jun 30, 2024 | 33.50 Mn |
| Jun 30, 2024 | 33.50 Mn |
| Mar 31, 2024 | 45.90 Mn |
| Mar 31, 2024 | 45.90 Mn |